07/02/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/2/2020. This four-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the Centers for Disease Control and Prevention (CDC)'s Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. Testing is to be conducted on specimens from individuals suspected of respiratory viral infection consistent with COVID-19 by a healthcare provider. Symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. (PDF)
No hay comentarios:
Publicar un comentario